"the deadline for submission for ASN was September 4, which as we know is well before the Phase 3 data would be known to RVX."

Correct. Similarly, the submission deadline for AHA late breaker submission was well before database lock and they received an AHA late breaker. And submission deadline for CTAD late breakers was the day after database lock was announced. Placeholders abstracts are allowed for late breaking clinical trial submissions. This is what they did for AHA. This is likely what they did for ASN. They must have submitted the cognition sub-study for CTAD during the normal submission period since it is already in the schedule (CTAD late breakers not announced yet).

"In that case, what exactly will the title of their presentation tell us about what the Phase 3 results were? Or is it just that the acceptance of RVX for late breaking clinical trial is good enough for now, that is cause enough for celebration?" The real deal will be when they present the data in the ASN conference?"

At this time, there is no Resverlogix/Apabetalone/BETonMACE presentation on the schedule for ASN. When late breaking titles are announced on Friday, we will know if this has changed. If they list a scheduled late breaking presentation, then we will know to expect an ASN presentation. Not on the schedule, no ASN presentation. And the title should reveal the topic. Confirmation of BETonMACE CKD sub-study would give a time stamp for when to expect these results. Of course, top-line for the CKD or cognition sub-studies could come before the presentation at ASN or CTAD (on schedule), respectively.

BearDownAZ